Clinical Features of Systemic Sclerosis–Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes

JL Fairley; D Hansen; S Proudman; J Sahhar; GS Ngian; J Walker; G Strickland; M Wilson; K Morrisroe; N Ferdowsi; G Major; J Roddy; W Stevens; M Nikpour; H Cooley; L Croyle; C Hill; L Host; S Lester; P Nash; M Rischmueller; T Tay; K Tymms; P Youssef

Journal article

Clinical Features of Systemic Sclerosis–Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes

JL Fairley, D Hansen, S Proudman, J Sahhar, GS Ngian, J Walker, G Strickland, M Wilson, K Morrisroe, N Ferdowsi, G Major, J Roddy, W Stevens, M Nikpour, H Cooley, L Croyle, C Hill, L Host, S Lester, P Nash Show all

Arthritis Care and Research | WILEY | Published : 2021

DOI: 10.1002/acr.24167

Download PDF

Abstract

Objective: To describe the clinical characteristics and outcomes of systemic sclerosis–mixed connective tissue disease (SSc–MCTD) and SSc overlap syndrome. Methods: We included patients from the Australian Scleroderma Cohort Study who met American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for SSc. Three mutually exclusive groups were created: SSc–MCTD, SSc overlap, and SSc only. Univariate comparison of clinical features was performed by analysis of variance or chi-square test. Survival analysis was performed using Kaplan-Meier (KM) curves and Cox proportional hazards regression models. Results: Of 1,728 patients, 97 (5.6%) had SSc–MCTD, and 126 (7.3..

View full abstract

University of Melbourne Researchers

Jessica Fairley Author

Katie Morrisroe Author

Wendy Stevens Author

Mandana Nikpour Author

Grants

Funding Acknowledgements

Dr. Morrisroe's work was supported by an Arthritis Australia Fellowship. Dr. Nikpour is recipient of a National Health and Medical Research Council Career Development Fellowship (grant APP1126370).The Australian Scleroderma Cohort Study is supported by Actelion, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, the Australian Rheumatology Association, the St. Vincent's Hospital Melbourne Research Endowment Fund, GlaxoSmithKline, Pfizer, Bristol Myers Squibb, Roche, and Bayer. The Australian Scleroderma Interest Group is supported by Actelion.